Tìm theo
Daunorubicin
Các tên gọi khác (10 ) :
  • (+)-Daunomycin
  • (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
  • Acetyladriamycin
  • Daunomycin
  • Daunorubicin
  • Daunorubicina
  • Daunorubicine
  • Daunorubicinum
  • Leukaemomycin C
  • Rubidomycin
Thuốc chống ung thư và tác động vào hệ thống miễn dịch
Thuốc Gốc
Small Molecule
CAS: 20830-81-3
ATC: L01DB02
ĐG : APP Pharmaceuticals , http://www.apppharma.com
CTHH: C27H29NO10
PTK: 527.5199
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. [PubChem]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C27H29NO10
Phân tử khối
527.5199
Monoisotopic mass
527.179146153
InChI
InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1
InChI Key
InChIKey=STQGQHZAVUOBTE-VGBVRHCVSA-N
IUPAC Name
(8S,10S)-8-acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
Traditional IUPAC Name
daunorubicin
SMILES
COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
Độ tan chảy
208-209 °C
Độ hòa tan
39.2 mg/L
logP
1.83
logS
-2.9
pKa (strongest acidic)
9.53
pKa (Strongest Basic)
8.94
PSA
185.84 Å2
Refractivity
132.89 m3·mol-1
Polarizability
52.94 Å3
Rotatable Bond Count
4
H Bond Acceptor Count
11
H Bond Donor Count
5
Physiological Charge
1
Number of Rings
5
Bioavailability
0
Dược Lực Học : Daunorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Daunorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Daunorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.
Cơ Chế Tác Dụng : A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. [PubChem] Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Daunorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
Dược Động Học :

▧ Protein binding :
97% binding-albumin
▧ Metabolism :
Hepatic
▧ Route of Elimination :
Twenty-five percent of an administered dose of daunorubicin hydrochloride is eliminated in an active form by urinary excretion and an estimated 40% by biliary excretion.
▧ Half Life :
18.5 hours
Độc Tính : LD50=20 mg/kg (mice, IV); LD50=13 mg/kg (rat, IV)
Chỉ Định : For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Tương Tác Thuốc :
  • Trastuzumab Trastuzumab may increase the cardiotoxicity of Daunorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Liều Lượng & Cách Dùng : Powder, for solution - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty : Sanofi-Aventis
    Sản phẩm biệt dược : Cerubidin
  • Công ty : Sanofi-Aventis
    Sản phẩm biệt dược : Cerubidine
  • Công ty : Sanofi-Aventis
    Sản phẩm biệt dược : Cérubidine
  • Công ty : Pfizer
    Sản phẩm biệt dược : Daunoblastin
  • Công ty : Pfizer
    Sản phẩm biệt dược : Daunoblastina
  • Công ty : GP-Pharm
    Sản phẩm biệt dược : Daunorrubicina
  • Công ty : Gilead
    Sản phẩm biệt dược : DaunoXome
  • Công ty : Varifarma
    Sản phẩm biệt dược : Maxidauno
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00694
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=30323
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508433
KEGG Compound
http://www.genome.jp/dbget-bin/www_bget?cpd:C01907
ChemSpider
http://www.chemspider.com/Chemical-Structure.28163.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0703-5233-13
PharmGKB
http://www.pharmgkb.org/drug/PA449212
Wikipedia
http://en.wikipedia.org/wiki/Daunorubicin
RxList
http://www.rxlist.com/cgi/generic2/daunorubicin.htm
Drugs.com
http://www.drugs.com/cdi/daunorubicin.html
... loading
... loading